Peer-reviewed veterinary case report
Advances in microbial mevalonolactone production: from fermentative mevalonate accumulation to downstream lactonization.
- Year:
- 2026
- Authors:
- Tang H et al.
- Affiliation:
- Suzhou Institute of Biomedical Engineering and Technology · China
Abstract
Mevalonolactone (MVAL) is a high-value feedstock for the cosmetic industry, with (<i>R</i>)-(-)-MVAL as the sole bioactive enantiomer. Chemical synthesis, which is the traditional method for MVAL production, is hindered by cumbersome procedures, low chiral purity, and sensitivity to humidity. Microbial fermentation <i>via</i> fermentative mevalonate (MVA) accumulation followed by <i>in vitro</i> acid-catalyzed lactonization has emerged as a promising alternative for producing optically pure (<i>R</i>)-(-)-MVAL. Strategies for MVA overproduction in microbial systems are reviewed, including the selection of chassis strains and enzymes for the MVA biosynthetic pathway, metabolic engineering approaches for strain improvement, optimization of fermentation processes, and downstream processes for MVA-to-MVAL lactonization. Finally, prospects for advancing microbial MVAL production are discussed.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://europepmc.org/article/MED/41982389